Drug Profile


Alternative Names: Ciclosporin G; Cyclosporin G; Nva2 cyclosporine; NVal CyA; OG 37325; SDZ 37325

Latest Information Update: 13 Oct 1997

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Ciclosporins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 13 Oct 1997 Clinical data have been added to the pharmacokinetic and pharmacodynamic sections.
  • 21 Jun 1996 A study has been added to the pharmacodynamics section
  • 19 Apr 1996 Discontinued-II for Systemic lupus erythematosus in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top